

Dysmenorrhea Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/DB7C2CB0776FEN.html>

Date: May 2024

Pages: 128

Price: US\$ 6,499.00 (Single User License)

ID: DB7C2CB0776FEN

Abstracts

The 7 major dysmenorrhea markets reached a value of US\$ 10.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 18.5 Billion by 2034, exhibiting a growth rate (CAGR) of 5.44% during 2024-2034.

The dysmenorrhea market has been comprehensively analyzed in IMARC's new report titled "Dysmenorrhea Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Dysmenorrhea is a medical condition characterized by painful menstrual periods. Some of the common indications of dysmenorrhea include cramping, lower abdominal pain, back pain, headache, nausea, vomiting, diarrhea, fatigue, etc. The pain can be intermittent or continuous and may start before or during menstruation. The severity of dysmenorrhea symptoms varies from woman to woman and month to month. Some women may also experience emotional indications, such as mood swings or irritability, during their menstrual period. The diagnosis of dysmenorrhea is typically made based on a woman's reported symptoms and medical history. A healthcare provider may ask about the timing and duration of menstrual pain, as well as the severity of indications and any associated factors, including nausea and fatigue. A physical exam is also conducted to check for any underlying medical conditions, such as pelvic inflammatory disease (PID), endometriosis, fibroids, etc., that may be contributing to the menstrual pain. In some cases, several imaging tests, including an ultrasound and MRI, may be suggested to further evaluate the reproductive organs.

The rising prevalence of various associated risk factors, including endometriosis, adenomyosis, fibroids, pelvic inflammatory disease (PID), cervical stenosis, ovarian cysts, etc., is primarily driving the dysmenorrhea market. In addition to this, the inflating

utilization of intrauterine devices (IUDs), which can cause irritation and inflammation, thereby leading to increased production of prostaglandins, is also augmenting the market growth. Moreover, the widespread adoption of nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, diclofenac, naproxen, ketoprofen, etc., for relieving menstrual cramps as well as reducing inflammation is creating a positive outlook for the market. Apart from this, the escalating usage of hormonal contraceptives, including birth control pills, rings, patches, etc., to help regulate the menstrual cycle and lower the severity of dysmenorrhea symptoms is acting as another significant growth-inducing factor. Additionally, various key players are making extensive investments in research activities to develop drugs that block the formation of prostaglandins, which are hormone-like substances responsible for causing uterine contractions and pain during menstruation. This, in turn, is expected to drive the dysmenorrhea market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the dysmenorrhea market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for dysmenorrhea and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the dysmenorrhea market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the dysmenorrhea market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the dysmenorrhea market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current dysmenorrhea marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the dysmenorrhea market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the dysmenorrhea market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the dysmenorrhea market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of dysmenorrhea across the seven major markets?

What is the number of prevalent cases (2018-2034) of dysmenorrhea by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of dysmenorrhea by gender across the seven major markets?

What is the number of prevalent cases (2018-2034) of dysmenorrhea by type across the seven major markets?

How many patients are diagnosed (2018-2034) with dysmenorrhea across the seven major markets?

What is the size of the dysmenorrhea patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of dysmenorrhea?

What will be the growth rate of patients across the seven major markets?

Dysmenorrhea: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for dysmenorrhea drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the dysmenorrhea market?

What are the key regulatory events related to the dysmenorrhea market?

What is the structure of clinical trial landscape by status related to the dysmenorrhea market?

What is the structure of clinical trial landscape by phase related to the dysmenorrhea market?

What is the structure of clinical trial landscape by route of administration related to the dysmenorrhea market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 DYSMENORRHEA - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
- 4.4 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
- 4.5 Competitive Intelligence

5 DYSMENORRHEA - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 DYSMENORRHEA - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (?2018-2023?)
 - 7.2.2 Epidemiology Forecast (?2024-2034?)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Epidemiology by Type (?2018-2034?)
 - 7.2.6 Diagnosed Cases (?2018-2034?)
 - 7.2.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (?2018-2023?)
 - 7.3.2 Epidemiology Forecast (?2024-2034?)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Epidemiology by Type (?2018-2034?)
 - 7.3.6 Diagnosed Cases (?2018-2034?)
 - 7.3.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (?2018-2023?)
 - 7.4.2 Epidemiology Forecast (?2024-2034?)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Epidemiology by Type (?2018-2034?)
 - 7.4.6 Diagnosed Cases (?2018-2034?)
 - 7.4.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (?2018-2023?)
 - 7.5.2 Epidemiology Forecast (?2024-2034?)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Epidemiology by Type (?2018-2034?)
 - 7.5.6 Diagnosed Cases (?2018-2034?)
 - 7.5.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (?2018-2023?)
 - 7.6.2 Epidemiology Forecast (?2024-2034?)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Epidemiology by Type (?2018-2034?)
 - 7.6.6 Diagnosed Cases (?2018-2034?)

- 7.6.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (?2018-2023?)
 - 7.7.2 Epidemiology Forecast (?2024-2034?)
 - 7.7.3 Epidemiology by Age (?2018-2034?)
 - 7.7.4 Epidemiology by Gender (?2018-2034?)
 - 7.7.5 Epidemiology by Type (?2018-2034?)
 - 7.7.6 Diagnosed Cases (?2018-2034?)
 - 7.7.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (?2018-2023?)
 - 7.8.2 Epidemiology Forecast (?2024-2034?)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Epidemiology by Type (?2018-2034?)
 - 7.8.6 Diagnosed Cases (?2018-2034?)
 - 7.8.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (?2018-2023?)
 - 7.9.2 Epidemiology Forecast (?2024-2034?)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Epidemiology by Type (?2018-2034?)
 - 7.9.6 Diagnosed Cases (?2018-2034?)
 - 7.9.7 Patient Pool/Treated Cases (?2018-2034?)

8 DYSMENORRHEA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 DYSMENORRHEA - UNMET NEEDS

10 DYSMENORRHEA - KEY ENDPOINTS OF TREATMENT

11 DYSMENORRHEA - MARKETED PRODUCTS

- 11.1 List of Dysmenorrhea Marketed Drugs Across the Top 7 Markets

11.1.1 Naprelan (Naproxen sodium) - Almatica Pharma

- 11.1.1.1 Drug Overview
- 11.1.1.2 Mechanism of Action
- 11.1.1.3 Regulatory Status
- 11.1.1.4 Clinical Trial Results
- 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 DYSMENORRHEA - PIPELINE DRUGS

12.1 List of Dysmenorrhea Pipeline Drugs Across the Top 7 Markets

12.1.1 DARE PDM1 - Dare Bioscience

- 12.1.1.1 Drug Overview
- 12.1.1.2 Mechanism of Action
- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status

12.1.2 Relugolix - Myovant/Takeda

- 12.1.2.1 Drug Overview
- 12.1.2.2 Mechanism of Action
- 12.1.2.3 Clinical Trial Results
- 12.1.2.4 Safety and Efficacy
- 12.1.2.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. DYSMENORRHEA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. DYSMENORRHEA – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 DYSMENORRHEA - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Dysmenorrhea - Market Size
 - 15.2.1.1 Market Size (?2018-2023?)
 - 15.2.1.2 Market Forecast (?2024-2034?)
 - 15.2.2 Dysmenorrhea - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (?2018-2023?)
 - 15.2.2.2 Market Forecast by Therapies (?2024-2034?)
- 15.3 Market Scenario - United States
 - 15.3.1 Dysmenorrhea - Market Size
 - 15.3.1.1 Market Size (?2018-2023?)
 - 15.3.1.2 Market Forecast (?2024-2034?)
 - 15.3.2 Dysmenorrhea - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (?2018-2023?)
 - 15.3.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.3.3 Dysmenorrhea - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Dysmenorrhea - Market Size
 - 15.4.1.1 Market Size (?2018-2023?)
 - 15.4.1.2 Market Forecast (?2024-2034?)
 - 15.4.2 Dysmenorrhea - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (?2018-2023?)
 - 15.4.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.4.3 Dysmenorrhea - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Dysmenorrhea - Market Size
 - 15.5.1.1 Market Size (?2018-2023?)
 - 15.5.1.2 Market Forecast (?2024-2034?)
 - 15.5.2 Dysmenorrhea - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (?2018-2023?)
 - 15.5.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.5.3 Dysmenorrhea - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Dysmenorrhea - Market Size
 - 15.6.1.1 Market Size (?2018-2023?)
 - 15.6.1.2 Market Forecast (?2024-2034?)
 - 15.6.2 Dysmenorrhea - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (?2018-2023?)
 - 15.6.2.2 Market Forecast by Therapies (?2024-2034?)

- 15.6.3 Dysmenorrhea - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Dysmenorrhea - Market Size
 - 15.7.1.1 Market Size (?2018-2023?)
 - 15.7.1.2 Market Forecast (?2024-2034?)
 - 15.7.2 Dysmenorrhea - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (?2018-2023?)
 - 15.7.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.7.3 Dysmenorrhea - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Dysmenorrhea - Market Size
 - 15.8.1.1 Market Size (?2018-2023?)
 - 15.8.1.2 Market Forecast (?2024-2034?)
 - 15.8.2 Dysmenorrhea - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (?2018-2023?)
 - 15.8.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.8.3 Dysmenorrhea - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Dysmenorrhea - Market Size
 - 15.9.1.1 Market Size (?2018-2023?)
 - 15.9.1.2 Market Forecast (?2024-2034?)
 - 15.9.2 Dysmenorrhea - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (?2018-2023?)
 - 15.9.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.9.3 Dysmenorrhea - Access and Reimbursement Overview

16 DYSMENORRHEA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 DYSMENORRHEA MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 DYSMENORRHEA MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Dysmenorrhea Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/DB7C2CB0776FEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DB7C2CB0776FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

